drugset / Trial / NCT00004333
Phase II Study of the Enzyme Inhibitor NTBC for Tyrosinemia Type I
Treatment
Summary
OBJECTIVES: Assess whether 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) at 0.6 mg/kg per day prevents liver failure in at least 1 patient with tyrosinemia type I.
Timeline
- Start
- 1994-11
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione | Unknown | 0.6 mg/kg | Oral |